Aethlon Medical Releases Smallpox Related Research Data

SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) today disclosed that researchers have completed in vitro studies that verify the ability of the Aethlon Hemopurifier® to effectively capture monkeypox virus (MPV). MPV represents a primary model to study candidate therapies for smallpox virus as research with human infectious smallpox is prohibited. In studies recently initiated by researchers, high concentrations of MPV (approximately 35 thousand cpu/ml) were rapidly depleted from cell culture fluids when circulated through the Hemopurifier®. The study data indicated that the Hemopurifier® removed 46 percent of infectious MPV in the first hour of testing, 82 percent after six hours, and 98 percent after 20 hours. The studies were conducted in triplicate and data verification was provided by real-time polymerase chain reaction (PCR). Smallpox is considered to be a Category “A” bioterror threat by the National Institute of Allergy and Infectious Diseases (NIAID).